Drug-drug Interaction Study of CHF5993 With Cimetidine

COPD Clinical Trial

Official title:

Open-label, Randomized, Single Dose, 2-sequence, 2-period Cross-over Study to Investigate the Effect of Inhibition of the Organic Cation Transport in the Kidneys by Cimetidine on the Pharmacokinetics of the CHF5993 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02287272
• Other study ID #: CCD-05993AA1-12
• Secondary ID: 2013-005491-18
• Status: Completed
• Phase: Phase 1
• Start date: May 2014
• Est. completion date: September 2014

Study information

• Verified date: October 2021
• Source: Chiesi Farmaceutici S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetic interaction when CHF5993 (pressurized metered-dose inhaler (pMDI) is administered with Cimetidine (probe inhibitor of the organic cation transport in the kidneys), by comparing the systemic exposure (AUC0-t) of Glycopyrronium Bromide (GB), after a single dose of the fixed combination CHF 5993 pMDI administered alone or at steady-state of Cimetidine

Description:

the safety and tolerability of study treatments based on evaluation of vital signs, electrocardiograms and clinical laboratory assessments will be also evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: September 2014
• Est. primary completion date: July 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Subject's written informed consent obtained prior to any study-related procedure;

2. Male and female healthy volunteers aged 18-45 years inclusive;

3. Male subjects with female partner of childbearing potential: they or their partner must be willing to use (at least) one or more reliable methods of contraception (see exclusion criterion n.1 for details*) from the time of dose administration and until the end of the study. Male subjects must not donate sperm for 90 days after the last dose of study drug. Male subjects with partners of non-childbearing potential are not required to use contraception;

4. Able to understand the study procedures, the risks involved and ability to be trained to correctly use the devices;

5. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2 inclusive;

6. A serum creatinine within the normal range (0,7-1,2 mg/dL) and an eGFR >80 mL/min/1.73 m2;

7. Non- or ex-smokers who smoked < 5 pack years (pack-years = the number of cigarette packs per day times the number of years) and stopped smoking > 1 year;

8. Good physical and mental status, determined on the basis of the medical history and a general clinical examination;

Exclusion Criteria:

1. Female subjects: pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS they meet the following definition of post-menopausal: 12 months of natural (spontaneous) documented amenorrhea or are willing to use one or more of the following reliable *methods of contraception:

1. surgical sterilization (e.g. bilateral tubal ligation, hysterectomy for females; vasectomy for males)

2. hormonal contraception (implantable, patch, oral), intrauterine device (IUD) or intrauterine system (IUS)

3. barrier methods (male or female condom, diaphragm, sponge, cervical cap).

2. Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;

3. Positive HIV1 or HIV2 serology;

4. Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C;

5. History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;

6. An abnormal triplicate 12-lead ECG (QRS> 120 msec, PR> 220 msec, HR < 40 bpm, HR > 110 bpm) at screening or at randomization;

7. Subjects whose electrocardiogram (12-lead ECG) shows QTcF >450 ms for males and >470 for females at screening or at randomization;

8. Subjects whose DBP is higher than 90 mmHg or SBP is higher than 140 mmHg at screening or at randomization;

9. Subjects who received any investigational new drug, or participated in clinical study within the last 8 weeks before screening;

10. History of hypersensitivity to M3 Antagonists, ß2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial;

11. Treatment within the previous 3 months before the screening visit until the end of the study procedures in the last treatment period with any drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole);

12. Subjects who refuse to abstain from alcohol or xanthine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to each intake of study medication until the end of confinement at the clinical centre;

13. Heavy caffeine drinker (> 5 cups or glasses of caffeinated beverages e.g., coffee, tea, cola per day);

14. Subjects who have a positive urine test for cotinine at screening.

Related Conditions & MeSH terms

• COPD

Intervention

Drug:
• CHF 5993 pMDI
4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
• Cimetidine plus CHF5993 pMDI
Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)

Locations

Country	Name	City	State
Belgium	Life Science Services SGS Belgium NV	Antwerp

Sponsors (1)

Lead Sponsor	Collaborator
Chiesi Farmaceutici S.p.A.

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Mariotti F, Ciurlia G, Spaccapelo L, Muraro A, Acerbi D. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993. Eur J Drug Metab Pharmacokinet. 20 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-t) of Glycopyrronium Bromide		pre-dose, 5, 10,15,30min, 1,2,4,6,8,12hr post-dose
Secondary	Other pharmacokinetic parameters for Glycopyrronium Bromide	Area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Glycopyrronium Bromide	pre-dose-72hr post-dose
Secondary	Other pharmacokinetic parameters for Formoterol	Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of Formoterol	pre-dose-24hr post dose
Secondary	Other pharmacokinetic parameters for B17MP	Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUC0-t), 0 to 24 hours (AUC0-24), 0 to 72 hours (AUC0-72) and 0 hours to infinity (AUC0-inf); maximum concentration (Cmax), time to maximum concentration (tmax), and apparent systemic clearance (CL/F) of B17MP	pre-dose- 72hr post-dose

External Links

•   CSR Synopsis available in the Chiesi Clinical Study Register